» Articles » PMID: 37363815

Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design

Overview
Journal Mov Disord
Date 2023 Jun 26
PMID 37363815
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In Parkinson's disease (PD), gait and balance is impaired, relatively resistant to available treatment and associated with falls and disability. Predictive models of ambulatory progression could enhance understanding of gait/balance disturbances and aid in trial design.

Objectives: To predict trajectories of ambulatory abilities from baseline clinical data in early PD, relate trajectories to clinical milestones, compare biomarkers, and evaluate trajectories for enrichment of clinical trials.

Methods: Data from two multicenter, longitudinal, observational studies were used for model training (Tracking Parkinson's, n = 1598) and external testing (Parkinson's Progression Markers Initiative, n = 407). Models were trained and validated to predict individuals as having a "Progressive" or "Stable" trajectory based on changes of ambulatory capacity scores from the Movement Disorders Society Unified Parkinson's Disease Rating Scale parts II and III. Survival analyses compared time-to-clinical milestones and trial outcomes between predicted trajectories.

Results: On external evaluation, a support vector machine model predicted Progressive trajectories using baseline clinical data with an accuracy, weighted-F1 (proportionally weighted harmonic mean of precision and sensitivity), and sensitivity/specificity of 0.735, 0.799, and 0.688/0.739, respectively. Over 4 years, the predicted Progressive trajectory was more likely to experience impaired balance, loss of independence, impaired function and cognition. Baseline dopamine transporter imaging and select biomarkers of neurodegeneration were significantly different between predicted trajectory groups. For an 18-month, randomized (1:1) clinical trial, sample size savings up to 30% were possible when enrollment was enriched for the Progressive trajectory versus no enrichment.

Conclusions: It is possible to predict ambulatory abilities from clinical data that are associated with meaningful outcomes in people with early PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Citing Articles

Glymphatic system dysfunction and risk of clinical milestones in patients with Parkinson disease.

Zhou C, Jiang X, Guan X, Guo T, Wu J, Wu H Eur J Neurol. 2024; 31(12):e16521.

PMID: 39425566 PMC: 11554988. DOI: 10.1111/ene.16521.


Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials.

Christine C, Auinger P, Forti E, Tat L, Cannizzaro N, Mustafa A J Parkinsons Dis. 2024; 14(6):1243-1255.

PMID: 39240650 PMC: 11380300. DOI: 10.3233/JPD-240035.


Knowledge mapping and research trends of accidental falls in patients with Parkinson's disease from 2003 to 2023: a bibliometric analysis.

Shi L, Yih B Front Neurol. 2024; 15:1443799.

PMID: 39239396 PMC: 11375799. DOI: 10.3389/fneur.2024.1443799.

References
1.
Lundberg S, Erion G, Chen H, DeGrave A, Prutkin J, Nair B . From Local Explanations to Global Understanding with Explainable AI for Trees. Nat Mach Intell. 2020; 2(1):56-67. PMC: 7326367. DOI: 10.1038/s42256-019-0138-9. View

2.
Morris R, Martini D, Madhyastha T, Kelly V, Grabowski T, Nutt J . Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease. Parkinsonism Relat Disord. 2019; 63:20-30. PMC: 6682416. DOI: 10.1016/j.parkreldis.2019.02.017. View

3.
Kieburtz K, Tilley B, Elm J, Babcock D, Hauser R, Ross G . Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015; 313(6):584-93. PMC: 4349346. DOI: 10.1001/jama.2015.120. View

4.
Stuart S, Morris R, Giritharan A, Quinn J, Nutt J, Mancini M . Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy. Mov Disord. 2020; 35(11):2019-2027. DOI: 10.1002/mds.28214. View

5.
Goetz C, Tilley B, Shaftman S, Stebbins G, Fahn S, Martinez-Martin P . Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23(15):2129-70. DOI: 10.1002/mds.22340. View